Inflammatory Bowel Diseases
Conditions
Brief summary
Secreted bacterial effectors produced by the intestinal microbiota are in part responsible for the proinflammatory effect of the fecal content in inflammatory bowel disease (IBD) patients.
Detailed description
Fecal colonic content will be collected by suction during routine colonoscopy. From the fecal content different fractions (containing soluble bacterial fractions and membrane bound bacterial fractions) will be processed. These bacterial fractions (also termed as bacterial secretome) will be tested for proinflammatory potential in tissue culture assays including epithelial colonic cell lines and dendritic/monocytic cell lines. The main outcome parameter will be the secretion of proinflammatory cytokines from the tissue culture. For this purpose the investigators will test different groups of patients including patients with active/inactive Crohn's disease or ulcerative colitis, patients with other inflammatory conditions of the colon, patients with colorectal carcinoma and healthy controls undergoing colonoscopy.
Interventions
OTHERColonic fluid collection during endoscopy for analysis of the bacterial secretome
Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
Sponsors
Medical University of Graz
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Group 1 (healthy controls): n=20 Inclusion criteria: * Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss * Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia
Exclusion criteria
* Diagnosis of IBD or any other inflammatory condition of the small and large intestine * Diagnosis of IBS * Autoimmune disorders * Obesity (BMI\> 30) * Regular intake of NSAIDs (\> 2 tablets/ week), immunosuppressants * Intake of antibiotics within the last 3 months * Intestinal infection by enteric pathogens * Probiotic therapy Group 2 (Crohn´s disease; CD): n= 20 (10 active CD; 10 inactive CD) Inclusion criteria: * Colonoscopy indicated by routine clinical care * Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of proinflammatory cytokines of bacterial fractions in IBD compared to healthy controls | One day | Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of proinflammatory cytokines of bacterial fractions in relation to disease activity | One day | Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays |
| Concentration of proinflammatory cytokines of bacterial fractions in relation to disease type | one day | Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays |
| Concentration of proinflammatory cytokines of bacterial fractions in other colonic diseases | One day | Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays |
Countries
Austria
Outcome results
None listed